产品说明
应用
L-798106, a selective prostanoid receptor EP3 antagonist, is used in prostanoid receptor signaling studies that regulate COX-2 levels and the central excitatory effects of PGE(2) on PVN neurons.
包装
5, 25 mg in glass bottle
生化/生理作用
L-798106 was among the first prostanoid receptor EP3-selective antagonists. It has been used in multiple studies to tease out EP3 agonist activity, both in vitro and in vivo. It successfully blocks the actions of sulprostone, an EP3-selective agonist, and it helped show that the vascular contraction effect of PGE2 is due to its prostanoid EP3 agonist activity.
特点和优势
This compound was developed by Merck & Co., Inc., Kenilworth, NJ, U.S.. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.
基本信息
| 经验(实验)分子式 | C27H22BrNO4S |
| 分子量 | 536.44 |
| MDL编号 | MFCD08272644 |
| PubChem化学物质编号 | 329817411 |
产品性质
| 质量水平 | 100 |
| 测定 | ≥98% (HPLC) |
| 形式 | powder |
| 溶解性 | DMSO: >20 mg/mL |
| 创始人 | Merck & Co., Inc., Kenilworth, NJ, U.S. |
| 储存温度 | 2-8℃ |
| SMILES string | COc1ccc(Br)cc1S(=O)(=O)NC(=O)\C=C\c2ccccc2Cc3ccc4ccccc4c3 |
| InChI | 1S/C27H22BrNO4S/c1-33-25-14-13-24(28)18-26(25)34(31,32)29-27(30)15-12-21-7-3-5-9-23(21)17-19-10-11-20-6-2-4-8-22(20)16-19/h2-16,18H,17H2,1H3,(H,29,30)/b15-12+ |
| InChI key | ODTKFNUPVBULRJ-NTCAYCPXSA-N |
安全信息
| 危险声明 | H413 |
| 预防措施声明 | P273 - P501 |
| 危险分类 | Aquatic Chronic 4 |
| 储存分类代码 | 13 - Non Combustible Solids |
| WGK | WGK 3 |
| 闪点(F) | Not applicable |
| 闪点(C) | Not applicable |
m.cnreagent.com
